Understanding prostate enlargement, urinary symptoms, hormonal influences and supportive care

As men age, changes in urinary function become increasingly common. But these changes should not automatically be blamed on the prostate. Symptoms such as needing to urinate more often, getting up several times at night, urgency, hesitancy, a weaker urinary stream, difficulty starting, or feeling that the bladder has not emptied completely are collectively known as lower urinary tract symptoms, or LUTS.

For many years, these symptoms were often treated almost synonymously with an enlarged prostate. We now understand that the picture is more complex. The prostate, bladder and lower urinary tract function as part of the same system, and symptoms may arise from prostate enlargement, bladder dysfunction, metabolic disease, infection, neurological conditions, medication effects or a combination of factors.

What actually changes with age?

The prostate commonly increases in size as men get older. The underlying tissue change is known as benign prostatic hyperplasia, or BPH, and when this results in an increase in prostate size it is often described as benign prostatic enlargement.

Importantly, prostate size does not always correspond to symptom severity. Some men have a relatively large prostate and few difficulties, while others experience troublesome urinary symptoms with only modest enlargement. What matters clinically is not simply whether the prostate is enlarged, but whether that enlargement is contributing to obstruction of urinary flow and how well the bladder itself is functioning.

Testosterone, DHT and prostate growth

The prostate is an androgen-sensitive organ. Within prostate tissue, testosterone can be converted by the enzyme 5-alpha-reductase into dihydrotestosterone, or DHT.

DHT is a more potent androgen that plays an important role in normal male development and continues to act in androgen-sensitive tissues such as the prostate, skin and hair follicles.

In the prostate, local DHT signalling helps maintain tissue growth and function. In genetically susceptible men, DHT can also contribute to male-pattern hair loss by gradually miniaturising scalp hair follicles, particularly around the temples and crown.

Because DHT binds strongly to androgen receptors, reducing its formation can be useful in some men with benign prostate enlargement. This is why 5-alpha-reductase inhibitor medicines are sometimes prescribed: lowering DHT within the prostate can gradually reduce prostate volume and help reduce the risk of progression in appropriately selected patients. But prostate ageing is not simply a story of “too much testosterone” or “too much DHT”.

And what about oestrogen?

Testosterone can also be converted by the enzyme aromatase into estradiol. This conversion occurs particularly in adipose tissue, so men with greater adiposity may have increased aromatisation.

Estradiol is not an unwanted hormone in men. It contributes to bone health, metabolic function and reproductive physiology. Within the prostate, however, its effects depend partly on which oestrogen receptor pathways are active.

Two important receptors are ERα and ERβ. ERα is expressed predominantly within the stromal compartment of the prostate, whereas ERβ is more prominent within epithelial cells. Experimental evidence suggests that ERα signalling can favour proliferative and inflammatory processes, while ERβ is more commonly associated with differentiation, growth restraint and anti-proliferative signalling.

The biology is not as simple as “ERα bad and ERβ good”, but the balance between these pathways appears to matter. Which receptor pathway predominates depends on more than the amount of circulating estradiol. It is influenced by the relative expression of ERα and ERβ, local hormone metabolism, receptor availability, inflammation, growth factors and the signalling environment within the tissue.

Diet may also influence oestrogen-receptor signalling both directly and indirectly. Phytoestrogens such as genistein show preferential activity at ERβ, while body composition, inflammation, local hormone metabolism and gut-microbial conversion of dietary compounds can all influence which receptor pathways predominate.

With ageing, testosterone often declines while oestrogenic activity may be relatively preserved, particularly where increased adiposity and metabolic dysfunction are present. This change in androgen–oestrogen balance, together with altered receptor signalling, may contribute to the hormonal environment in which prostate enlargement develops.

Can we influence ERβ signalling?

This is a particularly interesting area of emerging research. Genistein, an isoflavone found predominantly in soy, has long been known to interact more strongly with ERβ than ERα. But research suggests that its effects may extend beyond simply binding to an existing receptor.

In prostate cancer cell models, genistein at physiologically relevant concentrations was shown to reduce methylation of the ERβ gene promoter, resulting in increased ERβ gene expression and greater ERβ protein production. The researchers also observed increased ERβ activation and nuclear signalling, while blocking ERβ reduced the anti-proliferative effects of genistein.

In other words, genistein may not simply interact preferentially with ERβ — it may, under certain experimental conditions, help restore the expression of the receptor itself through an epigenetic mechanism. This is an intriguing finding because it suggests that dietary compounds may influence hormonal signalling not only through hormone concentrations or receptor binding, but also through regulation of receptor expression.

However, these findings come primarily from prostate cancer cell models. They should not be interpreted as evidence that genistein has been clinically proven to reverse BPH or to “switch” ERα signalling into ERβ signalling in men. They do, nevertheless, provide an interesting mechanistic rationale for investigating soy isoflavones and ERβ-supportive signalling in the ageing prostate.

The metabolic connection

Hormonal signalling cannot be separated from metabolic health. Obesity, insulin resistance, hypertension and chronic low-grade inflammation are all associated with male LUTS and BPH.

Adipose tissue is also an important site of aromatase activity, linking increasing visceral fat directly to changes in androgen–oestrogen balance. So when we assess prostate symptoms, it is useful to look beyond the gland itself and consider the wider picture:

• body composition
  
• blood pressure
  
• glucose regulation
  
• physical activity
  
• sleep
  
• cardiovascular healthmedications

This does not mean that improving metabolic health will automatically reverse prostate enlargement. It means that prostate symptoms frequently occur within a much broader physiological environment — and that environment is worth addressing.

How do we manage this?

The first step is to establish what is actually driving the symptoms. Assessment may include a detailed symptom history, medication review, urinalysis, prostate examination, PSA testing where appropriate, and further investigation if there are concerns about obstruction, infection, urinary retention, renal impairment or malignancy.

The current EAU approach to male LUTS also increasingly emphasises a broader symptom-based assessment rather than assuming that all urinary symptoms originate from prostate enlargement alone. For uncomplicated symptoms, management may include lifestyle measures, herbal medicine and conventional treatment where required.

Herbal medicine

Herbal treatment are individualised to the presentation rather than relying on a generic “prostate formula”. Some of the botanicals we may consider include:

• Serenoa repens — Saw palmetto - one of the best studied herbal medicines for LUTS associated with BPH.
• Urtica dioica radix — Nettle root - traditionally used for LUTS associated with BPH and particularly useful as part of an individualised formulation where irritative or inflammatory features are present.
• Epilobium angustifolium / Epilobium parviflorum — Willowherb - traditionally used for lower urinary tract symptoms associated with BPH and often considered where urinary irritation is prominent.
• Prunus africana — Pygeum - traditionally used for LUTS related to benign prostate enlargement, including frequency, nocturia and impaired urinary flow.
• Cucurbita pepo — Pumpkin seed - traditionally used for LUTS associated with BPH and overactive bladder symptoms.

Depending on the presentation, the wider formulation may also address inflammation, urinary tract irritation, pelvic circulation, stress physiology and metabolic health.

From a nutritional perspective, soy foods and genistein-containing preparations are particularly interesting because of the emerging ERβ and epigenetic research described above.

The aim is not simply to “shrink the prostate”, it is to understand and support the broader physiology contributing to the symptoms.

Diet and lifestyle

Some very practical changes can make a meaningful difference:

• maintain a healthy body weight
• improve insulin sensitivity and metabolic health
• exercise regularly
• reduce prolonged sedentary time
• moderate caffeine and alcohol, particularly later in the day
• adjust evening fluid intake if nocturia is troublesome
• avoid excessive fluid restriction, which may worsen urinary irritation
• identify individual bladder irritants
• maintain regular bowel function
• consider bladder training where urgency and frequency predominate

From a hormonal perspective, reducing excess visceral fat is particularly relevant because adipose tissue is a significant site of aromatisation of testosterone to estradiol.

Dietarily, I would favour a predominantly whole-food pattern rich in vegetables, legumes, whole grains, berries, nuts, seeds, good-quality fats and oily fish, while reducing excessive refined carbohydrate and ultra-processed food intake where metabolic dysfunction is present. Traditional soy foods such as tofu, tempeh and edamame may also provide isoflavones including genistein and daidzein.

And exercise?

Regular physical activity is particularly useful because prostate symptoms frequently coexist with central obesity, insulin resistance, cardiovascular disease and declining muscle mass.

A sensible programme can combine:

• resistance exercise to preserve muscle mass and metabolic function
• walking or aerobic activity to support cardiovascular fitness and insulin sensitivity
• regular movement throughout the day to reduce prolonged sedentary time
• pelvic floor and bladder training can also be useful, particularly where urgency, frequency or post-void dribbling are present. Pelvic floor exercises help improve muscular control around the bladder outlet, while bladder training gradually increases the time between voids and can reduce urgency. In men with persistent symptoms, pelvic floor physiotherapy may be helpful, especially where muscle coordination rather than simple weakness is the problem.

Exercise is not a direct treatment for BPH, but it can improve the wider metabolic environment in which urinary symptoms often develop.

Not every urinary symptom means BPH

This distinction is important.

• Frequency and urgency may arise from an overactive bladder.
• Nocturia can be influenced by evening fluid intake, sleep disorders, diabetes, cardiovascular disease or altered overnight urine production.
• A weak urinary stream may result from obstruction, but also from impaired bladder muscle function.
• Infection, stones and neurological disorders can produce overlapping symptoms.

So treating every man with urinary symptoms as though he simply has an enlarged prostate risks missing the actual cause.

And what about prostate cancer?

Benign prostate enlargement and prostate cancer are not the same condition, and BPH does not simply turn into cancer. However, some symptoms overlap, which is why persistent or changing urinary symptoms should be appropriately assessed rather than self-treated indefinitely. Symptoms deserving medical review include:

• blood in the urine
• recurrent urinary infection
• urinary retention
  
• significant or persistent pain
• rapid deterioration in urinary function
  
• an abnormal prostate examination or concern about prostate cancer

The Clinical Insight

The ageing prostate matters. But the better questions would be:

• What is causing the symptoms?
• Is there enlargement?
• Is there actual obstruction?
• How is the bladder functioning?
• What is happening hormonally — with testosterone, DHT, aromatisation and oestrogen-receptor signalling?
• Could metabolic health, inflammation, medication or another condition be contributing?
• And are there features that require further investigation?

Because good prostate care is not simply about treating a gland. It is about understanding the whole urinary, hormonal and metabolic system around it.

Wildberry Clinic | Men’s Health Series

Clinical herbal medicine grounded in science and individualised care.

This article is for educational purposes and does not replace individual medical assessment. New, persistent or worsening urinary symptoms should be appropriately investigated.

References

1. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. 2026 edition.
2. National Institute for Health and Care Excellence. Lower urinary tract symptoms in men: management. NICE Clinical Guideline CG97.
3. Mahmoud AM, Al-Alem U, Ali MM, Bosland MC. Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. Journal of Steroid Biochemistry and Molecular Biology. 2015;152:62–75. doi:10.1016/j.jsbmb.2015.04.018.
4. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82(4–5):184–199.
5. Novara G, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. European Urology Focus. 2016.
6. Vela-Navarrete R, et al. Efficacy and safety of a hexanic extract of Serenoa repens for LUTS associated with BPH: systematic review and meta-analysis. BJU International. 2018;122:1049–1065.
7. European Medicines Agency / HMPC monographs for Serenoa repens, Urtica dioica radix, Epilobium spp., Prunus africana and Cucurbita pepo in lower urinary tract symptoms associated with BPH; summarised in current EAU guidance.